Great Point Partners LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Great Point Partners LLC reported 26 stock positions worth $212.2 million. Its top holding was Ionis Pharmaceuticals (IONS) at 8.3% of the portfolio, followed by Cytokinetics (CYTK, 8.0%) and Kalvista Pharmaceuticals (KALV, 7.1%). Compared with Q3 2024, it opened 4 new positions, sold out of 7, added to 5 and reduced 13. The biggest buy was Ionis Pharmaceuticals (IONS, shares +98%) and the biggest sale Neurogene (NGNE, shares −56%).
- Most Recent 13F
- Q2 2026
- Location
- Greenwich, CT
- CIK
- 0001281446
- Portfolio Value
- $212.2M (Q4 2024)
- SEC Filing
- 0001172661-25-001157 ↗ filed Feb 14, 2025
Holdings Value
Holdings 26 stocks · $212.2M
| IONS Ionis Pharmaceuticals Inc. | 8.32% | 505,007 | $17.7M | Add +98.0% |
| CYTK Cytokinetics Inc. | 7.98% | 360,000 | $16.9M | Add +13.9% |
| KALV Kalvista Pharmaceuticals Inc. | 7.13% | 1,787,003 | $15.1M | Add +37.5% |
| VRDN Viridian Therapeutics Inc. | 6.78% | 750,000 | $14.4M | No change |
| PLRX Pliant Therapeutics Inc. | 6.55% | 1,055,000 | $13.9M | Reduce -44.8% |
| ABVX Abivax SA-ADR | 5.69% | 1,648,523 | $12.1M | Reduce -22.6% |
| DVAX Dynavax Technologies Corp. | 5.18% | 860,000 | $11.0M | Reduce -35.1% |
| NGNE Neurogene Inc. | 4.77% | 442,761 | $10.1M | Reduce -55.9% |
| EOLS Evolus Inc. | 4.66% | 895,524 | $9.9M | Reduce -23.5% |
| XENE Xenon Pharmaceuticals Inc. | 4.53% | 245,272 | $9.6M | New |
| UNICYCIVE THERAPEUTICS INC | 4.11% | 10,980,000 | $8.7M | Add +28.3% |
| ZURA Zura Bio Ltd. | 3.73% | 3,170,194 | $7.9M | Reduce -2.9% |
| AUTL Autolus Therapeutics PLC | 3.33% | 3,009,392 | $7.1M | Add +7.0% |
| JSPR Jasper Therapeutics Inc. | 3.25% | 322,380 | $6.9M | No change |
| MRUS Merus NV | 3.13% | 158,092 | $6.6M | Reduce -36.8% |
| DNTH Dianthus Therapeutics Inc. | 2.83% | 275,000 | $6.0M | No change |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 2.47% | 500,000 | $5.3M | No change |
| UPB Upstream Bio Inc. | 2.32% | 300,000 | $4.9M | New |
| CNTX Context Therapeutics Inc. | 2.32% | 4,683,711 | $4.9M | Reduce -32.5% |
| VYGR Voyager Therapeutics Inc. | 2.21% | 826,751 | $4.7M | Reduce -13.9% |
| ORKA Oruka Therapeutics Inc. | 2.09% | 228,803 | $4.4M | Reduce -55.5% |
| MREO Mereo Biopharma Group PL-ADR | 1.90% | 1,150,000 | $4.0M | New |
| RZLT Rezolute Inc. | 1.44% | 621,894 | $3.0M | New |
| PMN Promis Neurosciences Inc. | 1.18% | 2,645,128 | $2.5M | Reduce -5.2% |
| OPTINOSE INC | 1.17% | 370,269 | $2.5M | Reduce -56.8% |
| URGN Urogen Pharma Ltd. | 0.94% | 187,843 | $2.0M | Reduce -75.2% |
Portfolio Sells Q3 2024 → Q4 2024
| NGNE Neurogene Inc. | Reduce -55.9% | 4.77% | −7.95 |
| OLMA Olema Pharmaceuticals Inc. | Sold out | 0.00% | −3.60 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −2.52 |
| OTLK Outlook Therapeutics Inc. | Sold out | 0.00% | −2.08 |
| URGN Urogen Pharma Ltd. | Reduce -75.2% | 0.94% | −1.97 |
| CNTX Context Therapeutics Inc. | Reduce -32.5% | 2.32% | −1.78 |
| ORKA Oruka Therapeutics Inc. | Reduce -55.5% | 2.09% | −1.72 |
| ABVX Abivax SA-ADR | Reduce -22.6% | 5.69% | −1.71 |
| TCRX Tscan Therapeutics Inc. | Sold out | 0.00% | −1.53 |
| OPTINOSE INC | Reduce -56.8% | 1.17% | −1.43 |
| EOLS Evolus Inc. | Reduce -23.5% | 4.66% | −1.06 |
| RNAC Cartesian Therapeutics Inc. | Sold out | 0.00% | −0.97 |
| MRUS Merus NV | Reduce -36.8% | 3.13% | −0.64 |
| VTGN Vistagen Therapeutics Inc. | Sold out | 0.00% | −0.61 |
| CLYM Climb Bio Inc. | Sold out | 0.00% | −0.38 |
| ZURA Zura Bio Ltd. | Reduce -2.9% | 3.73% | −0.26 |
| PLRX Pliant Therapeutics Inc. | Reduce -44.8% | 6.55% | +0.09 |
| PMN Promis Neurosciences Inc. | Reduce -5.2% | 1.18% | +0.13 |
| VYGR Voyager Therapeutics Inc. | Reduce -13.9% | 2.21% | +0.51 |
| DVAX Dynavax Technologies Corp. | Reduce -35.1% | 5.18% | +0.72 |
Portfolio Buys Q3 2024 → Q4 2024
| IONS Ionis Pharmaceuticals Inc. | Add +98.0% | 8.32% | +5.24 |
| XENE Xenon Pharmaceuticals Inc. | New | 4.53% | +4.53 |
| UNICYCIVE THERAPEUTICS INC | Add +28.3% | 4.11% | +3.06 |
| CYTK Cytokinetics Inc. | Add +13.9% | 7.98% | +2.95 |
| KALV Kalvista Pharmaceuticals Inc. | Add +37.5% | 7.13% | +2.59 |
| UPB Upstream Bio Inc. | New | 2.32% | +2.32 |
| MREO Mereo Biopharma Group PL-ADR | New | 1.90% | +1.90 |
| RZLT Rezolute Inc. | New | 1.44% | +1.44 |
| AUTL Autolus Therapeutics PLC | Add +7.0% | 3.33% | +0.25 |
Options Activity Q3 2024 → Q4 2024
| ACLX Arcellx Inc. | put | Sold out | 100,000 | $8.4Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $424.4M | VOR, ABVX, VERA, ZURA, ALMS |
| Q1 2026 | 39 | $408.3M | APGE, VOR, ZURA, AMLX, NKTR |
| Q4 2025 | 29 | $308.4M | APGE, AMLX, ZURA, IRON, RAPT |
| Q3 2025 | 28 | $239.5M | AMLX, RZLT, NKTR, ZURA, SLNO |
| Q2 2025 | 26 | $153.8M | IONS, RZLT, AMLX, LEGN, ABVX |
| Q1 2025 | 31 | $184.0M | CYTK, KALV, EOLS, ABVX, VRDN |
| Q4 2024 | 26 | $212.2M | IONS, CYTK, KALV, VRDN, PLRX |
| Q3 2024 | 29 | $331.4M | NGNE, ABVX, PLRX, EOLS, VRDN |
| Q2 2024 | 33 | $522.0M | URGN, NGNE, ABVX, MRUS, PLRX |
| Q1 2024 | 35 | $641.6M | NGNE, ALPN, URGN, ABVX, EOLS |